Strategic acquisition Combinati was acquired by Thermo Fisher Scientific in 2021, indicating a strong validation of its digital PCR technology and potential for deeper integration and cross-selling opportunities within Thermo Fisher’s customer base.

Product-market fit The company emphasizes a simple, robust digital PCR platform with high accuracy and minimal waste, suggesting a strong appeal to researchers seeking ease of use and scalable quantification for disease biomarkers.

Funding and scale With $5.8M in funding and revenue under $1M, there is room to support scalable outreach, pilot programs, and case studies to accelerate commercialization through Thermo Fisher channels.

Targeted outreach Key selling angles include democratization of digital PCR, compatibility with traditional qPCR assays, and false positive rejection, which can resonate with academic labs, hospitals, and diagnostic developers seeking affordable, accurate dPCR solutions.

Market positioning As a niche, high-precision biotechnologies provider with limited current staffing, partnerships with established distributors or service-backed models could accelerate adoption across research institutions and biotech firms that rely on digital PCR for biomarker monitoring.